off-the-shelf– tag –
-
Off-the-Shelf CAR T Therapies Revolutionize Cancer Treatment: Simplifying Manufacturing with Healthy Donor Cells, Reducing Wait Times and Costs
Katie Couric Media USA Overview Next-generation allogeneic CAR T-cell therapy, or 'off-the-shelf CAR T,' utilizes healthy donor cells instead of patient-specific cells, enabling large-batch manufacturing and extended storage. This signif... -
In Vivo CAR-T Cell Therapy Demonstrates Clinical Proof-of-Concept with AI Acceleration: Enabling Direct In-Body Immune Cell Gene Editing Towards ‘Off-the-Shelf Biologics’
OncoDaily International Overview While autologous CAR-T cell therapy yields durable remissions in B-cell malignancies, its delivery model faces persistent challenges. In vivo CAR-T emerges as a radically different approach, delivering CA... -
Chinese Scientists Achieve Breakthrough: Mass Production of 14 Million NK Immune Cells from a Single Stem Cell, Paving Way for ‘Off-the-Shelf’ Immunotherapy
Facebook (referencing a February 2026 breakthrough in China) China Overview In February 2026, Chinese scientists announced a breakthrough, successfully mass-producing an astounding 14 million natural killer (NK) immune cells in the lab f... -
INFORMA Database Analysis Reveals Rapid Growth of Allogeneic NK Cell Immunotherapy, CAR-Engineered NK Cells Transitioning to Standardized Platforms
INFORMA database (journal article) International Overview Natural killer (NK) cell-based immunotherapy is gaining increasing prominence as a cancer treatment strategy due to its inherent cytotoxicity, allogeneic potential, and compatibil... -
AstraZeneca Accelerates Next-Gen Cell Therapy Manufacturing: Gracell’s Rapid Platform Reduces Autologous CAR T Production Time
AstraZeneca UK Overview AstraZeneca is addressing critical challenges in cell therapy by accelerating autologous cell therapy manufacturing and advancing allogeneic and in vivo 'off-the-shelf' approaches. Notably, they are leveraging Gra... -
Liv Hospital Details Advanced ‘Off-the-Shelf’ CAR-T Manufacturing, Promising Scalability and Broader Access
Liv Hospital Turkey Overview Liv Hospital has unveiled its detailed manufacturing process for allogeneic, 'off-the-shelf' CAR-T cell therapy, a significant leap towards overcoming the logistical and cost barriers of current personalized ... -
CellFiber and Tidewave Bio Partner to Evaluate 3D Cell Culture Platform for Scalable Manufacturing of Next-Gen Cell Immunotherapies
BioProcess International Global Overview CellFiber and Tidewave Bio have initiated a joint Proof of Concept (PoC) to evaluate CellFiber's 3D cell culture platform for scalable manufacturing of Tidewave's next-generation cell immunotherap... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph... -
Rapid Rise of iPSC-Based Therapies: Manufacturing Challenges and FUJIFILM Cellular Dynamics’ Automation Solutions
Contract Pharma International Overview iPSC-based therapies are rapidly advancing as a renewable, standardized source for allogeneic treatments and scalable solutions across various indications. However, manufacturing poses challenges in... -
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene...
